8-KEarnings & ResultsOther EventsExhibits & Filings

DEXCOM INC 8-K Report, Financial Results (Jan 10, 2022)

Filed January 10, 2022For Securities:DXCM

Summary

DexCom, Inc. (DXCM) announced preliminary, unaudited financial results for the fourth quarter and full fiscal year 2021, alongside an initial outlook for fiscal year 2022. The company expects fourth-quarter 2021 revenue to be approximately $698 million, representing a 23% increase year-over-year. For the full fiscal year 2021, preliminary revenue is projected to exceed $2.448 billion, a growth of over 27% compared to 2020. This demonstrates strong top-line performance and continued market traction for DexCom's products. Looking ahead, DexCom provided an initial revenue outlook for fiscal year 2022, anticipating a range of $2.82 billion to $2.94 billion. This guidance suggests continued growth momentum. Additionally, the company presented promising clinical data for its next-generation interoperable Continuous Glucose Monitoring (CGM) system, achieving summary mean absolute relative difference (MARD) of 8.2% in adults and 8.1% in pediatrics from its U.S. pivotal trial, indicating potential advancements in accuracy and performance.

Key Highlights

  • 1Preliminary Q4 2021 revenue estimated at approximately $698 million, up 23% year-over-year.
  • 2Full fiscal year 2021 preliminary revenue expected to exceed $2.448 billion, up over 27% year-over-year.
  • 3Initial fiscal year 2022 revenue guidance provided, projecting $2.82 billion to $2.94 billion.
  • 4Positive clinical data reported for next-generation interoperable CGM, with MARD of 8.2% in adults and 8.1% in pediatrics.
  • 5Results presented at the J.P. Morgan Virtual 40th Annual Healthcare Conference.
  • 6Preliminary results are subject to finalization in the upcoming Form 10-K.
  • 7Forward-looking statements are included, subject to risks and uncertainties.

Frequently Asked Questions

DexCom anticipates preliminary, unaudited revenue of approximately $698 million for the fourth quarter of 2021, a 23% increase over Q4 2020. For the full fiscal year 2021, preliminary revenue is expected to be over $2.448 billion, representing growth of more than 27% compared to 2020.

DexCom has provided an initial revenue outlook for fiscal year 2022, with an anticipated range for total revenue between $2.82 billion and $2.94 billion.

DexCom presented clinical data from its U.S. pivotal trial for its next-generation interoperable CGM. The results showed a summary mean absolute relative difference (MARD) of 8.2% in adults and 8.1% in pediatrics, indicating potential improvements in accuracy.

No, the financial results presented are preliminary and unaudited. They are subject to finalization in connection with the preparation of DexCom's Annual Report on Form 10-K for the twelve months ended December 31, 2021.